Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Heiman

Gastroenterology Tampa, FL Medical Doctor

NPI 1750385407 CMS profile 125099

4224 N Tampania Ave, Tampa, FL 33607

Open in the dashboard

General payments

$17,189

869 records reported · program years 2019–2025

Research payments

$1,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Heiman of Tampa, FL is reported in the CMS Open Payments database as having received $17,189 across 869 general payments and $1,500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,355 105
2024 General $2,360 109
2023 General $2,420 119
2022 General $2,985 157
2021 General $3,190 158
2020 General $1,763 98
2020 Research $1,500 1
2019 General $2,118 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Heiman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Heiman were reported at $2,355. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Heiman Gastroenterology median Middle half National median
2019 $2,118 $417 $126–$1,100 $163
2020 $1,763 $224 $74–$624 $114
2021 $3,190 $352 $106–$1,054 $132
2022 $2,985 $448 $129–$1,270 $149
2023 $2,420 $533 $150–$1,390 $160
2024 $2,360 $605 $160–$1,606 $164
2025 $2,355 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $4,543 227 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,101 116 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $2,039 108 payments
  4. Janssen Biotech, Inc. $1,596 76 payments
  5. Gilead Sciences, Inc. $792 43 payments
  6. RedHill Biopharma Inc. $677 35 payments
  7. Celgene Corporation $562 35 payments
  8. Merck Sharp & Dohme Corporation $541 26 payments
  9. VIVUS, Inc. $474 25 payments
  10. Nestle HealthCare Nutrition Inc. $472 27 payments
  11. Other $3,392 151 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,591 858 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $300 1 payment
  3. Education $231 8 payments
  4. Honoraria $50 1 payment
  5. Consulting Fee $17 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,868 98 payments
  2. STELARA $1,490 71 payments
  3. CREON $1,368 79 payments
  4. LINZESS $1,357 75 payments
  5. ENTYVIO $1,290 64 payments
  6. SKYRIZI $1,154 39 payments
  7. RINVOQ $1,125 65 payments
  8. HUMIRA $803 44 payments
  9. SIMPONI $685 27 payments
  10. SIMPONI ARIA $673 25 payments
  11. Other $10,851 539 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

959

Median for Gastroenterology: 569

Drug cost

$55,388

Median for Gastroenterology: $104,976

Branded share of claims

12.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 23 $23,659
Mesalamine Generic 26 $9,631
Omeprazole Generic 451 $6,410
Ursodiol Generic 19 $4,805
Ondansetron Odt Ondansetron Brand 67 $3,067
Pantoprazole Sodium Generic 183 $2,191
Esomeprazole Magnesium Generic 55 $1,826
Dicyclomine Hcl Generic 46 $1,254
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 20 $875
Famotidine Generic 28 $851

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$95,419

Medicare's payments for the services billed

Medicare patients

500

Average age 75

Services billed

1,086

267 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 46%
Diabetes 27%
Chronic kidney disease 26%
Depression 22%
Cancer 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$280 — —
LINZESS
$243 23 —
RINVOQ
$231 — —
ENTYVIO
$212 — —
OMVOH
$167 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

870 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record